To assess the effectiveness of increasing the numbers of drugs in antiretroviral combination therapy. Searching MEDLINE, the Cochrane Library, EMBASE, CINAHL, PsycLIT, and HealthSTAR were searched up to the end of February 2001. Appropriate Internet sites such as AIDSTRIALS were searched, as were citation lists. Pharmaceutical companies were also contacted. Studies reported in any language were considered.
are available on the BMJ website (accessed 21/10/2002). See Web Address at the end of this abstract. Viral loads and CD4 counts were measured at the longest time point, when at least half of the total number of patients in each arm remained. The treatment effect for continuous outcomes was calculated for individual trials as the difference in mean change (treatment minus control). In trials with several treatment arms, the number of events and the number of participants were weighted so that each participant was used only once.
Methods of synthesis
How were the studies combined? Studies were grouped according to the regimens compared. The continuous data were pooled using the inverse variance method of weighting. The event rates were pooled using the fixed-effect method of Yusuf et al. (see Other Publications of Related Interest no.2), to give pooled odds ratios (ORs) and 95% confidence intervals (CIs). Significance was set at a p-value of less than 0.05 for event rates. Publication bias was assessed visually using a funnel plot, and statistically using Egger's and Begg's tests.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the chi-squared test. Heterogeneity was investigated using sensitivity and subgroup analyses and fixed-effect weighted regression techniques, using the following factors as covariates: trial duration; baseline CD4 count or viral load; drop-out rates; drug dose; specific drug or drugs (protease inhibitors or zidovudine); change in CD4 count or viral load; sensitivity of the viral load assay; and blinding and concealment of allocation.
Results of the review
Fifty-four RCTs (20,404 patients) were included.
The trials were generally of a good quality. In one third of the trials, concealment of allocation was confirmed; most were double-blind; and the treatment groups were comparable within trials. Follow-up was not always clearly reported (additional data presented on the BMJ website; see Web Address at end of abstract).
Quadruple therapy: no fully published evidence on the effectiveness of quadruple or higher therapies was found.
Monotherapy (zidovudine) versus placebo or no treatment (18 comparisons, 7,929 patients). Zidovudine significantly reduced disease progression or death (OR 0.7, 95% CI: 0.6, 0.8). Significant heterogeneity was found (chi-squared 25.47, d.f.=14, Z=5.02). Heterogeneity was partly explained by the duration of the trials; as trials increased in length, zidovudine had a smaller relative effect. Zidovudine resulted in an improved CD4 count of 47 cells/microL (95% CI: 29, 65) and no significant heterogeneity was found. The viral load was also significantly reduced with zidovudine but significant heterogeneity was found.
Double therapy versus monotherapy (16 comparisons, 5,084 patients).
Double therapy significantly reduced disease progression or death when compared with monotherapy (OR 0.6, 95% CI: 0.5, 0.7). Significant heterogeneity was found (chi-squared 22.16, d.f.=15, Z=6.44). Heterogeneity appeared to be largely accounted for by one large RCT of protease inhibitors, but excluding this RCT did not alter the results. The duration of the trials did not explain the heterogeneity. Double therapy led to significantly improved results for CD4 counts and viral load when compared with monotherapy. Significant heterogeneity was found for both outcomes, but this was wholly accounted for by the presence of zidovudine or protease inhibitors. Triple therapy versus double therapy (9 comparisons, 3,671 patients).
Triple therapy significantly reduced disease progression or death when compared with double therapy (OR 0.6, 95% CI: 0.5, 0.8). Most trials had few events. Significant heterogeneity was found (chi-squared 8.52, d.f.=8, Z=4.21). Heterogeneity appeared to be largely accounted for by one open-label RCT, but excluding this RCT did not alter the results. Triple therapy led to significantly improved results for CD4 counts and viral load when compared with double therapy. Significant heterogeneity was found for both outcomes. The possible causes were quality criteria, i.e. concealment of allocation and non-blinding, and the types of drugs used. There was no consistent visual or statistical evidence of publication bias, except for CD4 count for triple versus double therapy.
Drop-outs (26 RCTs).
The drop-out rates were higher with monotherapy compared with placebo, but were similar between double and monotherapy. The results for triple therapy compared with double therapy were inconsistent. The quality of life results (4 RCTs) were inconsistent.
